Skip to main content

Table 1 SNPs mapping to epigenetic marks used to define enhancers in prostate and breast cancer

From: Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer

Cell line/Tumor type

Epigenetic marks

Key transcription factora

Number of SNPs within the intervals covered by the array:

iCOGS

PRACTICAL

BCAC

All

LNCaP

H3K27Ac

----

1605

3092

13482

13503

AR

669

1274

5664

5671

LNCaP

H3K27Ac + MED12

----

685

1271

5428

5442

AR

279

541

2310

2316

VCaP

H3K27Ac + BRD4

----

587

983

4218

4239

AR

342

502

2148

2154

VCaP

BRD4

----

859

1595

7984

8066

AR

23

60

233

233

VCaP

H3K27Ac

----

3896

8440

38150

38444

PC

H3K27Ac + MED12 + BRD4

----

82

130

618

619

AR

49

46

248

249

PC

----

AR

496

1403

5950

5967

MCF7

H3K27Ac + BRD4

----

8783

21058

93969

94858

ER

4296

10607

45937

46222

MCF7

H3K27Ac

----

19270

48028

215997

217382

ER

6710

16206

69743

70058

MCF7

BRD4

----

280

495

2617

2641

ER

34

66

282

282

MCF7

----

ER

158

371

1638

1639

  1. aBinding information for key transcription factors such as androgen receptor (AR) or estrogen receptor (ER) where used alone or in combination with the epigenetic mark profiles in order to assess their capacity to refine enrichment of risk SNPs